Riad Sherif, Chief Executive Officer of Oculis (OCS), stated, “We began 2026 with strong execution momentum across our late-stage clinical trials. We are positioned for a pivotal year, with key readouts for OCS-01 in diabetic macular edema expected in June and Licaminlimab in dry eye disease around year-end, while the Privosegtor PIONEER program is making significant progress, including PRIME designation in Europe and an agreement with the FDA on the Special Protocol Assessment regarding PIONEER-1 and ongoing centers activation. Driven by a mission to restore vision, we are targeting global market opportunities exceeding $30 billion.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results
- Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes
- Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing
- Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session
- Oculis Buy Rating Reiterated on De-Risked Phase 3 DIAMOND Program and Blockbuster Potential of Topical DME Therapy OCS-01